• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Acta Pharm Sin B. D3Targets-2019-nCoV: a webserver for predicting drug targets and for multi-target and multi-site based virtual screening against COV

tetano

Editor, Senior Moderator
Acta Pharm Sin B. 2020 Apr 20. doi: 10.1016/j.apsb.2020.04.006. [Epub ahead of print]
D3Targets-2019-nCoV: a webserver for predicting drug targets and for multi-target and multi-site based virtual screening against COVID-19.


Shi Y[SUP]1,[/SUP][SUP]2[/SUP], Zhang X[SUP]1[/SUP], Mu K[SUP]1,[/SUP][SUP]3[/SUP], Peng C[SUP]1,[/SUP][SUP]2[/SUP], Zhu Z[SUP]1,[/SUP][SUP]2[/SUP], Wang X[SUP]1[/SUP], Yang Y[SUP]1,[/SUP][SUP]2[/SUP], Xu Z[SUP]1,[/SUP][SUP]2[/SUP], Zhu W[SUP]1,[/SUP][SUP]2[/SUP].

Author information




Abstract

A highly effective medicine is urgently required to cure coronavirus disease 2019 (COVID-19). For the purpose, we developed a molecular docking based webserver, namely D3Targets-2019-nCoV, with two functions, one is for predicting drug targets for drugs or active compounds observed from clinic or in vitro/in vivo studies, the other is for identifying lead compounds against potential drug targets via docking. This server has its unique features, (1) the potential target proteins and their different conformations involving in the whole process from virus infection to replication and release were included as many as possible; (2) all the potential ligand-binding sites with volume larger than 200 ?[SUP]3[/SUP] on a protein structure were identified for docking; (3) correlation information among some conformations or binding sites was annotated; (4) it is easily to be updated, and is accessible freely to public (https://www.d3pharma.com/D3Targets-2019-nCoV/index.php). Currently, the webserver contains 42 proteins [20 severe acute respiratory syndrome-related coronavirus 2 (SARS-CoV-2) encoded proteins and 22 human proteins involved in virus infection, replication and release] with 69 different conformations/structures and 557 potential ligand-binding pockets in total. With 6 examples, we demonstrated that the webserver should be useful to medicinal chemists, pharmacologists and clinicians for efficiently discovering or developing effective drugs against the SARS-CoV-2 to cure COVID-19.
? 2020 Chinese Pharmaceutical Association and Institute of Materia Medica, Chinese Academy of Medical Sciences. Production and hosting by Elsevier B.V.



KEYWORDS:

COVID-19; D3Targets-2019-nCoV; Multi-conformation; Multi-site; SARS-CoV-2; Target prediction; docking


PMID:32318328PMCID:PMC7169934DOI:10.1016/j.apsb.2020.04.006
Free full text
 
Back
Top Bottom